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Abstract 
Prolonged critically ill patients present with distinct alterations in calcium and bone 
metabolism. Circulating bone formation markers are reduced and bone resorption markers are 
substantially elevated, indicating an uncoupling between osteoclast and osteoblast activity, 
possibly resulting in pronounced bone loss, impaired traumatic or surgical fracture healing 
and osteoporosis. In addition, we have previously shown that increased circulating osteoclast 
precursors in critically ill patients result in increased osteoclastogenesis in vitro, possibly 
through FcγRIII signaling. In the current study, we investigated the effects of sustained 
critical illness on bone metabolism at the tissue level in a standardized rabbit model of 
prolonged (7 days), burn injury-induced critical illness. This in vivo model showed a 
reduction in serum ionized calcium and osteocalcin levels, as is seen in humans. Trabecular 
area, bone mineral content and density were decreased in sick rabbits [by 43% (p<0.01), 31% 
(p<0.01) and 29% (p<0.05), respectively], as was the trabecular gene expression of osteoblast 
and angiogenesis markers, indicating decreased bone formation and impaired vascularization. 
There was no change in the expression of osteoclast differentiation markers from the 
canonical RANK/RANKL/OPG pathway, however, there was an increase in expression of 
markers from the non-canonical, immunoreceptor tyrosine-based activation motif (ITAM) 
signaling pathway, FcγRIII and DAP12 (148% and 59%, respectively; p<0.01). The current 
study has shown a detrimental effect of prolonged critical illness on trabecular bone integrity, 
possibly explained by reduced osteoblast differentiation and angiogenesis, coupled with 
increased osteoclastogenesis signaling that may be mediated via the non-canonical 
immunoreceptor tyrosine-based activation motif signaling pathway. 
Keywords 
Intensive Care Unit; bone hyperresorption; osteoclast; osteoblast; ITAM 
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1 Introduction 
Advances in intensive care medicine over the past decades have made it possible for patients to 
survive a variety of previously lethal insults such as surgery, trauma, sepsis or extensive burn injury 
[1, 2]. However, this has also created a growing population of patients who evolve towards a phase of 
prolonged critical illness, where they remain dependent upon vital organ function support for weeks or 
months. This chronic phase brings about a therapy-resistant catabolic state that is hallmarked by lean 
tissue wasting, skeletal muscle weakness and non-resolving multiple organ failure [1-3].  
Normal bone turnover depends on a tight coupling between the function of mature osteoclasts, 
osteoblasts and vascularization, requiring a complex equilibrium of immune, endocrine, mechanical 
and nutritional factors [4]. The bone remodeling cycle is a closely regulated and carefully orchestrated 
sequence that involves coordinated communication between osteoblasts and osteoclasts [5]. Critically 
ill patients display vitamin D deficiency, hypocalcaemia, elevated levels of inflammatory cytokines 
such as tumor necrosis factor α (TNF-α), interleukin-1 (IL-1) and IL-6, and marked alterations in 
markers of bone metabolism [6-8]. More specifically, during prolonged critical illness levels of bone 
formation markers such as osteocalcin are low, and levels of bone resorption markers such as carboxy-
terminal cross-linked telopeptide of type I collagen are 6- to 15-fold increased. The degree of these 
alterations during critical illness is much higher than in classic metabolic diseases, such as 
postmenopausal osteoporosis, where only a 2-fold increase in bone resorption markers is observed [9]. 
Consequently, prolonged critically ill patients may be predisposed to inefficient traumatic or surgical 
fracture healing and to osteoporosis. Indeed, a recent retrospective case-cohort study revealed a 
significant increase in fracture risk among survivors of critical illness [10]. 
We recently showed that peripheral blood mononuclear cells (PBMCs) isolated from critically ill 
patients reveal an increased osteoclastogenic potential and differentiate into mature osteoclasts in vitro 
much more than cells from healthy subjects [11]. Moreover, the activity of the patients’ mature 
osteoclasts appeared dependent on humoral factors present in the serum of critically ill patients. In 
particular, circulating humoral factors depending on signaling through ITAM receptors of the non-
canonical pathway for osteoclastogenesis appeared to play a key role [12]. In inflammatory bone 
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disorders such as rheumatoid arthritis, it has been shown that the expression of two 
immunomodulatory ITAM receptors, DNAX-activation protein 12 (DAP12) and Fc receptor common 
γ chain III (FcγRIII), is increased [13]. Blocking FcγRIII in vitro decreased osteoclast formation in 
PBMCs from critically ill patients, suggesting that immunomodulatory factors present in patient serum 
may induce abberant osteoclast formation. 
Although biomarkers in human patients suggest excessive bone loss during critical illness [8], as yet 
the in vivo effect of prolonged critical illness on bone integrity has not been documented. We assessed 
the effects of critical illness on trabecular bone in a well validated rabbit model of prolonged critical 
illness [14]. The current study showed a detrimental effect of critical illness on trabecular bone, 
possibly due to impaired osteoblast differentiation and activated osteoclastogenesis evoked by 
signaling through the ITAM signaling pathway.  
 
2 Materials and Methods 
2.1 Animals and blood analysis 
The study protocol was approved by the KU Leuven Ethical Review Board for Animal Research 
(P108/2009). All animals were treated according to the Principles of Laboratory Animal Care (U.S. 
National Society for Medical Research) and the Guide for the Care and Use of Laboratory Animals 
(National Institutes of Health). The rabbit model of prolonged (7days) critical illness has been 
described in detail previously [14]. At day -1, adult, 3- to 4-month-old male New Zealand White 
rabbits (n=40) were anesthetized and catheters were inserted in the right jugular vein and right carotid 
artery, allowing intravenous infusion of fluids and repetitive blood sampling, respectively. Fluid 
resuscitation consisting of Hartmann (Baxter, Lessines, Belgium), enriched with 5% glucose to 
prevent hypoglycemia, was started after the operation. At day 0, animals were anesthetized again, and 
after having performed a paravertebral block with lidocaine (Xylocaine, AstraZeneca, Brussels, 
Belgium), a full thickness third-degree burn injury was inflicted on the flanks (15–20% body surface 
area; painless by itself as cutaneous nerves for sensation of pain are destroyed). Hartmann-Glucose 
was changed to total parenteral nutrition [33.3% Oliclinomel N7 (Baxter), 33.3% Hartmann, and 
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33.3% Glucose 50%] at day 1. This model closely mimics the (neuro)endocrine, metabolic and clinical 
abnormalities of critically ill patients and has therefore been validated as representative of the human 
critically ill condition [4, 14]. Ionized calcium levels were measured immediately by blood gas 
analysis (ABL 725, Radiometer, Copenhagen, Denmark) peroperatively at day -1, before burn injury 
at day 0 and from day 1 every morning. At the same time, a daily 4 ml blood sample was collected and 
plasma was stored at -80°C until further analysis. Animals surviving until day 7 (n=30) were 
anesthetized and were sacrificed by cardiectomy. Animals entering a preterminal state before day 7 
(n=10), as evidenced clinically and by blood gas analysis, were anesthetized and sacrificed at that 
time. The left and right tibiae were dissected, dipped in polyvinyl alcohol and snap-frozen in liquid 
nitrogen, and stored at -80°C until further analysis. For comparison, healthy rabbits (n=15) were 
sacrificed and tissue samples were collected as described above. These rabbits did not receive a burn 
injury, were not catheterized and had free access to standard chow. In every experiment, all critically 
ill rabbits (survivors and non-survivors) are compared to the healthy controls, unless otherwise 
indicated. Plasma osteocalcin was measured by an in-house rabbit osteocalcin radioimmunoassay as 
previously described [8, 15].  
2.2 Bone quantification 
Peripheral quantitative computed tomography (pQCT; Stratec XCT Research densitometer, Norland 
Medical Systems, Fort Atkinson, WI, USA) was used to assess trabecular bone mineral content 
(BMC) and density (BMD) and the geometry of the proximal right tibia from critically ill rabbits 
(n=27 survivors and 7 non-survivors) and healthy controls (n=15) ex vivo. Using a voxel size of 0.070 
mm, slices of 0.2 mm thickness were obtained. Three metaphyseal scans were taken 2.4 mm from the 
proximal end of the tibia to measure trabecular volumetric density. An inner threshold was set to 30% 
of the total cross-sectional area to define the trabecular bone region. Following pQCT, the proximal 
tibiae of these rabbits were decalcified in 10% EDTA at 4°C in order to enable sectioning of tissues 
[16]. After 6 weeks, the tibiae were processed to paraffin and sections of 5 µm thickness were cut. 
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2.3 Histological and immunohistochemical analysis of rabbit trabecular bone 
Sections from the right proximal tibia from 15 healthy controls and prolonged critically ill rabbits 
were stained for H&E, and the amount of trabecular bone quantified by ImageJ® software (National 
Institutes of Health) [17]. The amount of demineralized, mature bone vs. unmineralized osteoid or 
immature bone present was histologically analyzed through a Masson’s Trichrome stain as previously 
described [18]. The amount of immature bone (red color) vs. mature bone (blue color) was visualized 
using fluorescent microscopy and quantified using an in-house software tool. Osteoclast activity was 
quantified visually with tartrate-resistant acid phosphatase (TRAP), as previously described [11]. The 
osteoclastogenic marker FcγRIII was detected by immunohistochemistry with goat-anti-rabbit 
polyclonal antibody (1:200; Antibodies-online, Aachen, Germany), followed by probing with donkey 
anti-goat IgG (1:500; Jackson Immunoresearch, West Grove, PA, USA). FcγRIII-positive cells were 
visualized and quantified manually. 
2.4 RNA isolation and quantitative PCR 
Gene expression analysis was performed on the trabecular bone of the right tibia of critically ill rabbits 
(n=3 survivors and 2 non-survivors) and healthy controls (n=5). Total RNA was isolated using the 
RNeasy mini RNA isolation kit (QIAGEN) according to manufacturer’s instructions and quantified by 
Nanodrop ND-1000 Spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA). In total, 1 
µg RNA was reverse-transcribed using SuperScript III Reverse Transcriptase (Invitrogen, Merelbeke, 
Belgium). All samples were reverse transcribed simultaneously. mRNA levels were quantified in real-
time using the StepOnePlus™ Real-Time PCR System (Applied Biosystems, Chershire, UK). SYBR® 
Green qPCR primers were designed using the software program Primer3 (Whitehead Institute for 
Biomedical Research, Cambridge, MA, USA) to span an intron so that only RNA-specific 
amplification was possible (Table S1). The gene expression of 3 osteogenic markers, namely runt-
related transcription factor 2 (RUNX2), osterix (OSX) and collagen type I alpha 1 (COL1A1) was 
measured. For osteoclastogenesis, the gene expression of markers of 2 different signaling pathways 
was measured: receptor activator of nuclear factor kappa-B ligand (RANKL), as well as its receptor 
RANK and decoy receptor osteoprotegerin (OPG) as markers of the canonical RANK/RANKL/OPG 
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pathway, and DAP12 and FcγRIII, both involved in the alternative ITAM signaling pathway. Vascular 
endothelial growth factor receptor 1 (VEGFR1) and VEGFR2 represent two markers of angiogenesis. 
Unknown samples were run in triplicate. Relative fold changes in expression were calculated using the 
∆Ct method [19]. Gene expression of housekeeping gene hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) was used as an internal control. 
2.5 Statistical analysis 
Data are presented as mean ± standard error of the mean (SEM), median and interquartile ranges box 
plots, with 10th and 90th percentiles or as numbers and percentages. Student’s t test was used for the 
comparison of normally distributed data and the Mann-Whitney U test for data that were not normally 
distributed. All statistical analyses were calculated using Statview 5.0.1. software (SAS Institute Inc., 
Cary, NC, USA). Statistical significance is indicated on all graphs as follows: *: p<0.05, **: p<0.01, 
***: p<0.001. 
  
3 Results   
3.1 Serum ionized calcium and plasma osteocalcin levels are decreased in critically ill rabbits 
In order to confirm that the in vivo rabbit model of prolonged critical illness utilized in the current 
study was a suitable representation of bone metabolism in prolonged critically ill humans, we 
measured serum ionized calcium and plasma osteocalcin levels. As in critically ill patients, serum 
ionized calcium was significantly reduced in critically ill rabbits (Fig. 1A).  Infliction of the critical 
illness evoked an immediate decrease in ionized calcium on day 1 (3%; p<0.01), which remained 
lower than in healthy rabbits for the 7-day period of illness. In addition, plasma osteocalcin levels 
were significantly lowered in critically ill rabbits by day 4 of illness [by 62% (p<0.001)] (Fig. 1B), 
similar to what is seen in critically ill patients. The survivor status of the critically ill rabbits did not 
significantly affect the results (data not shown). 
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3.2 Trabecular bone is reduced in critically ill rabbits 
In order to examine the direct effect of critical illness on the skeleton, BMC and BMD were analyzed 
ex vivo in the proximal tibia through pQCT. Importantly, trabecular BMC and BMD were significantly 
lower in critically ill rabbits than in healthy controls [31% (p<0.01) and 29% (p<0.05), respectively] 
(Fig. 1C, D). The reduction in trabecular bone was confirmed histologically with a significant 43% 
reduction (p<0.001) in average trabecular area in critically ill rabbits as compared to healthy controls 
(Fig. 1E, F). Survivor status of the critically ill rabbits did not significantly affect these results (data 
not shown).  
3.3 Histological increases in osteoclast activity are undetectable in trabecular bone at day 7 in 
critically ill rabbits  
Masson’s Trichrome staining did not reveal a difference in the amount of mature and immature bone 
present in critically ill rabbits as compared to healthy controls (Fig. 2A). In addition, TRAP staining 
and FcγRIII immunohistochemistry failed to show any significant difference in the number of active 
osteoclasts in the trabecular bone of the proximal tibiae of critically ill rabbits and healthy controls 
(Fig. 2B, C). We cannot exclude that increases in osteoclast activity may have occurred at earlier time 
points. 
3.4 Critically ill rabbits present with a decrease in gene expression of osteogenic and angiogenic 
markers and an increase in markers of the osteoclastogenic ITAM signaling pathway  
To investigate osteoblast differentiation further, the gene expression of RUNX2, OSX and COL1A1 
was measured in the trabecular bone of prolonged critically ill and healthy control rabbits. The 
expression of these 3 markers was significantly decreased in the critically ill rabbits as compared to 
healthy controls [by 55% (p<0.05), 61% (p<0.01) and 74% (p<0.01), respectively] (Fig. 3A-C). 
VEGFR1 and -2 gene expression was measured as a marker of angiogenesis during critical illness. 
VEGFR2 expression was significantly decreased in critically ill rabbits as compared to healthy 
controls (59%; p<0.01), while the expression of VEGFR1 displayed a trend towards a reduction, 
although did not reach significance (58%; p=0.08) (Fig. 3D, E). Osteoclastogenesis was assessed 
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through the gene expression of markers of 2 different signaling pathways, from which the canonical 
RANK/RANKL/OPG pathway is the most common osteoclastogenic pathway. A significant reduction 
in the gene expression of RANKL in the critically ill rabbits as compared to healthy controls was 
observed (62%; p<0.01), along with a trend for a decreased expression of OPG (63%; p=0.07), 
resulting in an unchanged OPG/RANKL ratio, suggesting this pathway may be unaltered during 
critical illness (Fig. 4A-C). An alternative osteoclastogenic ITAM signaling pathway, including 
FcγRIII and DAP12 as 2 important ITAM receptors, is known to be involved in diseases of extreme 
bone resorption [12, 20], and interestingly, gene expression of FcγRIII and DAP12 was increased 
significantly (148% and 59%, respectively; p<0.01) (Fig. 4D, E). Survivor status of the critically ill 
rabbits did not significantly affect these results (data not shown). 
 
4 Discussion 
During prolonged critical illness levels of bone formation markers are low, and levels of bone 
resorption markers are 6- to 15-fold increased. Critical illness, whether or not evoked by burn injuries, 
is characterized by a marked hypermetabolic response, hypercatabolism, and a severe loss of lean 
body mass [21]. A mouse model with burn injury displayed a 59% reduction in trabecular BMC 
compared to controls after 10 days [22]. In addition, a number of studies have shown that children 
with burn injuries exceeding 40% total body surface area are subject to abnormalities in bone and 
calcium metabolism including acute and chronic bone loss, early post-burn hypocalcaemia and 
hypoparathyroidism [23]. The bone loss is manifested by an approximate 2% loss of total body BMC 
2 months after the burn injury, increasing to 3% by 6 months, with lumbar spine BMC falling by 8% 
after 2 months. However, while the catabolic state eventually resolves, BMD remains low in these 
children for years following the burn injury [24], resulting in an increased risk of fracture. These 
findings suggest a direct association between the extreme catabolic state experienced during critical 
illness or burn injury and subsequent skeletal morbidity. This is confirmed by a recent retrospective 
longitudinal case-cohort study by Orford and colleagues revealing an increased risk of fragility 
fractures over an 8-year period in elderly female survivors of critical illness [10]. We recently reported 
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in an in vitro study using human cells that impaired angiogenesis and osteoclastic abnormalities most 
likely mediated by immunomodulatory factors through the non-canonical ITAM signaling pathway, 
may contribute to critical illness related bone loss in the intensive care unit [11]. In the current study, 
we sought to confirm and further investigate these findings in an in vivo rabbit model of critical 
illness. 
As previously reported, the rabbit model of prolonged critical illness mirrors many of the endocrine 
and metabolic changes observed in critically ill patients [14]. In the current study, critically ill rabbits 
displayed low levels of serum ionized calcium throughout the 7-day period of illness. During critical 
illness in patients, abnormalities in ionized calcium levels are common, with 90% of patients 
displaying mild hypocalcaemia, although hypercalcaemia has also been reported in the prolonged 
phase of illness, particularly when renal failure is present [25]. The observed reduction in plasma 
osteocalcin in critically ill rabbits after 4 days is also in line with findings in critically ill patients [8], 
suggesting that bone formation may be reduced during critical illness. This was confirmed by the 
current study, in which the trabecular bone in tibiae of critically ill rabbits revealed a 31% and 29% 
reduction of mineral content and density, respectively, and a 43% decrease in area as compared with 
healthy control rabbits. It has been shown that corticosteroid treatment can produce osteoporosis with 
25 mg of prednisone on alternate days leading to an average reduction of 3.5% of trabecular bone over 
1 year [26], and similarly, in a rabbit model of osteoporosis evoked by methylprednisolone, trabecular 
BMD was reduced by 36% after 10 weeks of treatment [27]. Therefore, our observation of reduced 
trabecular bone after only 7 days of critical illness is remarkable. It is possible that such a large 
decrease in trabecular bone could be due, in part, to immobilization, which induces skeletal unloading 
leading to an imbalance between bone resorption and bone formation, resulting in trabecular bone loss 
[28]. However, in the current study, rabbits have adequate space for limited movement, and critically 
ill rabbits are able to use their front- and hind-limbs to support their weight. Critically ill patients are 
also immobilized for long periods of time, however a recent study showed only a 2-fold increase in the 
bone resorption marker beta-carboxy-terminal crosslinking telopeptide I (β-CTX-I) in patients that 
were immobilized by stroke for 6 months, suggesting that immobilization alone cannot explain the 
remarkable 6-fold increase in bone resorption markers that is observed in prolonged critical illness 
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[29]. Surprisingly, the reduction in trabecular BMC and BMD was not associated with an increase in 
TRAP- or FcγRIII-positive multinuclear osteoclasts. It is possible that increases in osteoclast activity 
may have occurred at earlier time points, resulting in the extreme bone loss observed. 
In other metabolic bone diseases such as Paget’s disease of bone and osteoporosis, reduction in 
trabecular BMD is thought to be caused by an ‘uncoupling’ between bone forming osteoblasts and 
bone resorbing osteoclasts. In the current study, there was a significant decrease in the expression of 
early (RUNX2 and OSX) and late (COL1A1) markers of osteoblast differentiation. This finding, 
coupled with a reduction in the expression of angiogenesis marker VEGFR2 suggests a potential 
rationale for the reduction in trabecular bone observed, and confirms our previous in vivo study where 
a reduction in bone formation and vascularization was observed in patient serum-treated human 
periosteal derived cells seeded onto calcium phosphate scaffolds and implanted into mice for 8 weeks 
[11]. Recently, it has been shown that healthy human PBMCs can be subdivided into two subsets, 
FcγRIII-positive and -negative monocytes, from which the latter is known to differentiate into mature 
osteoclasts in vitro only after stimulation with RANKL and macrophage colony-stimulating factor M-
CSF [30]. However, it has been shown that there is an upregulation of circulating FcγRIII-positive 
monocytes in inflammatory bone diseases. These cells represented the major reservoir of osteoclast 
precursors in inflammatory diseases and the level of FcγRIII expression correlated with the bone 
resorption activity [12]. In critically ill patients, we have previously shown that osteoclast precursors 
differentiate into mature active osteoclasts even in the absence of RANKL and MCSF, suggesting that 
the majority of circulating monocytes in critically ill patients are FcγRIII-positive. This was confirmed 
when, by blocking the FcγRIII receptor in critically ill PBMCs in vitro, aberrant osteoclast formation 
was ameliorated [11]. These data imply that during critical illness, osteoclastogenesis is potentially 
due to circulating humoral factors and/or IgG antibodies and driven through the non-canonical ITAM 
signaling pathway rather than the common RANK/RANKL/OPG pathway [11]. Interestingly, in some 
inflammatory diseases of bone hyperresorption such as psoriatic arthritis, rheumatoid arthritis and 
osteoporosis, alternative signaling via the ITAM receptors FcγRIII and DAP12 has been proposed as 
the pathway through which osteoclast formation and activity is stimulated [13, 31, 32]. Although in 
the current study, OPG/RANKL ratio was unchanged and no significant differences in TRAP staining 
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or FcγRIII immunohistochemistry could be detected after 7 days of illness, there was a significant 
increase in the gene expression of FcγRIII and DAP12 (148% and 59%, respectively). This supports 
the hypothesis that signaling through the canonical pathway was unaffected by critical illness, 
however, the observed critical illness-induced reduction in trabecular bone may be mediated via non-
canonical ITAM signaling pathway-driven osteoclastogenesis.  
 
5 Conclusions 
The present study has investigated bone metabolism at tissue level during critical illness in a validated 
animal model for prolonged critical illness. The critical illness-related reduction in trabecular bone 
may result from osteoclastic bone hyperresorption mediated through the non-canonical ITAM 
signaling pathway combined with a decrease in osteoblast formation and angiogenesis (Figure S1).  
These findings may help to define novel therapeutic targets to prevent critical illness-induced bone 
loss.  
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Figure Legends 
Figure 1. Blood analysis and trabecular bone quantification of the proximal tibiae in critically ill 
rabbits. (A) Serum ionized calcium levels were reduced from day 1 (by 3%) in critically ill rabbits 
(grey dots; mean ± SEM; n=40) and remained lower than in healthy rabbits (white dots; n=15) for the 
7-day period of illness. (B) Plasma osteocalcin levels were significantly lower in critically ill rabbits 
(grey box plots; n=40) as compared to healthy controls (white box plots; n=15) by day 4 of illness 
(62%). Quantification by pQCT revealed that trabecular BMC (C) and BMD (D) were significantly 
lower in critically ill rabbits (grey box plots; n=34) than in healthy controls (white box plots; n=15) 
(31% and 29%, respectively). (E) H&E staining of the proximal tibiae of critically ill rabbits and 
healthy controls (n=10 for both groups). (F) Quantification of the H&E staining using ImageJ® 
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revealed a significant reduction (43%) in trabecular area in critically ill rabbits as compared to healthy 
controls. Data in panels B-F are represented as box plots, with medians, interquartile ranges and 10th 
and 90th percentiles; * p<0.05; ** p<0.01; *** p<0.001.  
Figure 2. Histological and immunohistochemical analysis of critically ill rabbit trabecular bone. 
(A) Masson’s Trichrome stain did not reveal a difference in the amount of unmineralized osteoid or 
immature bone (red) and demineralized, mature bone (blue) present in critically ill rabbits compared to 
healthy controls (scale bar=200µm). TRAP staining (B) (scale bar=100µm) and FcγRIII 
immunohistochemistry (C) (scale bar=50µm) of the proximal tibia did not show a significant 
difference in the number of active osteoclasts (black arrows) in the trabecular bone of critically ill 
rabbits and healthy controls. n=10 for both groups. 
Figure 3. Expression of osteogenic and angiogenic markers in critically ill rabbit trabecular 
bone. The expression of 3 osteogenic markers, RUNX2 (A), OSX (B) and COL1A1 (C) were 
significantly reduced in critically ill rabbits as compared to healthy controls (by 55%, 61% and 74%, 
respectively). Angiogenesis markers VEGFR1 (D) and VEGFR2 (E) also revealed a decrease in 
critically ill rabbits as compared to healthy controls (58% and 59%, respectively). n=5 for both groups; 
* p<0.05; ** p<0.01. 
Figure 4. Expression of osteoclast markers in critically ill rabbit trabecular bone.  (A) RANKL 
expression was significantly reduced in critically ill rabbits as compared to healthy controls (by 62%); 
there was a trend (p=0.07) for decreased expression in OPG (B), resulting in no change in the 
OPG/RANKL ratio (C). The gene expression FcγRIII (D) and DAP12 (E), were significantly 
increased (148% and 59%, respectively) in critically ill rabbits as compared to healthy controls. n=5 
for both groups; * p<0.05; ** p<0.01. 
Figure S1. Proposed mechanism of bone loss during prolonged critical illness. The reduction in 
trabecular bone during critical illness is possibly a direct result of bone hyperresorption through 
aberrant osteoclast formation that may be mediated via the non-canonical ITAM signaling pathway, 
combined with a decrease in osteoblast formation and angiogenesis. (Dotted lines represent unchanged 
signaling; full lines represent increased reactions). 
Table S1. Sequences of qPCR primers  
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Table S1. Sequences of qPCR primers. 
 
GENE NAME SEQUENCE 
Osteogenic markers 
RUNX2 
Forward: 5’- CTTCACAAATCCTCCCCAAG-3’ 
Reverse: 5’- ATGCGCCCTAAATCACTGAG-3’ 
OSX 
Forward: 5’- ATGGCGTCCTCTCTGCTTG-3’ 
Reverse: 5’- GCTTCTTCGTGCCTGCTTT-3’ 
COL1A1 
Commercial gene expression assay, Applied Biosystems 
Reference number: OC03396116_A1 
Osteoclastogenic markers 
Canonical RANK/RANKL/OPG pathway 
OPG 
Forward: 5’-GTGCACTTGGTTTGCTGCTA-3’ 
Reverse: 5‘-CCTGAAGAATGCCTCCTCAC-3’ 
RANK 
Forward: 5’- GCAGTTCCTCTCTGCCATCT-3’ 
Reverse: 5’- AGTGCCTTCCCTTGTTTCCT-3’ 
RANKL 
Forward: 5’-AAAATGAAGATTTGCAAGACG-3’ 
Reverse: 5’-TTTCTCGGCTCTCAGGTGTT-3’ 
Non-canonical ITAM signaling pathway 
DAP12 
Forward: 5’- CTGGTGTTGACCCTGCTCAT-3’ 
Reverse: 5’- TGACTCGGTCTCAGTGATGC-3’ 
FcγRIII 
Forward: 5’- GACCTCCACATTCCAGAAGC-3’ 
Reverse: 5‘-GAGAACGGAGGACGAGATGA-3’ 
Angiogenic markers 
VEGFR1 
Forward: 5’-CAAGCCGGACAGACACTGTA-3’ 
Reverse: 5’-GCAGGTGGATTTCGAGATGT-3’ 
VEGFR2 
Forward: 5’-GCAAGAAGGGTTTCAGCATC-3’ 
Reverse: 5’-GCTCACCAGCACGTCATAAA-3’ 
Housekeeping gene 
HPRT 
Forward: 5’-TGTAGATTTTATCAGACTGAAGAGCTACTGT-3’ 
Reverse: 5’- AAGGAAAGCAAGGTCTGCATTGTT-3’ 
